0

Purvalanol A

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP212844536-A
CAS212844-53-6
Structure
MDL NumberMFCD02179211
Molecular Weight388.89
InChI KeyPMXCMJLOPOFPBT-HNNXBMFYSA-N
Description≥98% (HPLC), powder
Solubilitymethylene chloride: 50 mg/mL
Assay≥98% (HPLC)
Formpowder
Size1MG
Storage Conditions−20°C
1

Purvalanol A Is a Strong Apoptotic Inducer via Activating Polyamine Catabolic Pathway in MCF-7 Estrogen Receptor Positive Breast Cancer Cells

Pınar Obakan, Elif Damla Arısan, Pelin Özfiliz, Ajda Çoker-Gürkan, Narçin Palavan-Ünsal

Mol Biol Rep. 2014 Jan;41(1):145-54.

PMID: 24190492

1

Purvalanol A, a CDK Inhibitor, Effectively Suppresses Src-mediated Transformation by Inhibiting Both CDKs and c-Src

Tomoya Hikita, Chitose Oneyama, Masato Okada

Genes Cells. 2010 Oct;15(10):1051-62.

PMID: 20825494

1

Purvalanol A, Olomoucine II and Roscovitine Inhibit ABCB1 Transporter and Synergistically Potentiate Cytotoxic Effects of Daunorubicin in Vitro

Daniela Cihalova, Jakub Hofman, Martina Ceckova, Frantisek Staud

PLoS One. 2013 Dec 23;8(12):e83467.

PMID: 24376706

1

The Cdc2/Cdk1 Inhibitor, Purvalanol A, Enhances the Cytotoxic Effects of Taxol Through Op18/stathmin in Non-Small Cell Lung Cancer Cells in Vitro

Xian Chen, Ying Liao, Dan Long, Ting Yu, Fang Shen, Xuechi Lin

Int J Mol Med. 2017 Jul;40(1):235-242.

PMID: 28534969

1

The CDK Inhibitor Purvalanol A Induces Neutrophil Apoptosis and Increases the Turnover Rate of Mcl-1: Potential Role of p38-MAPK in Regulation of Mcl-1 Turnover

P Phoomvuthisarn, A Cross, L Glennon-Alty, H L Wright, S W Edwards

Clin Exp Immunol. 2018 May;192(2):171-180.

PMID: 29377076

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode